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CXCR4 Negatively Regulates Keratinocyte
Proliferation in IL-23-Mediated Psoriasiform
Dermatitis
Tomonori Takekoshi1,2, Xuesong Wu1, Hiroshi Mitsui2, Yayoi Tada2, Mandy C. Kao1, Shinichi Sato2,
Michael B. Dwinell3 and Sam T. Hwang1
CXCR4 is expressed by basal keratinocytes (KCs), but little is known about its function in inflamed skin. We
crossed K14-Cre and CXCR4flox/flox (f/f) transgenic mice, resulting in mice with specific loss of the CXCR4 gene in
K14-expressing cells (K14-CXCR4KO), including basal KCs. K14-CXCR4KO pups had no obvious skin defects. We
compared K14-CXCR4KO and CXCR4f/f control mice in an IL-23-mediated psoriasiform dermatitis model and
measured skin edema, and histologic and immunohistological changes. IL-23-treated K14-CXCR4KO mice showed
a 1.3-fold increase in mean ear swelling, a 2-fold increase in epidermal thickness, and greater parakeratosis. IL-23-
treated wild-type (WT) mice showed weak CXCR4 expression in areas of severe epidermal hyperplasia, but strong
CXCR4 expression in nonhyperplastic regions, suggesting that CXCR4 may regulate KC proliferation. To test this
hypothesis, we overexpressed CXCR4 in HaCaT KC cells and treated them with IL-22 and/or CXCL12 (chemokine
(C-X-C motif) ligand 12). CXCL12 blocked IL-22-mediated HaCaT cell proliferation in vitro and synergized with
IL-22 in upregulating SOCS3 (suppressor of cytokine signaling 3), a key regulator of STAT3 (signal transducer and
activator of transcription 3). SOCS3 was required for CXCR4-mediated growth inhibition. In human psoriatic skin,
both CXCR4 and SOCS3 were upregulated in the junctional region at the border of psoriatic plaques. Thus,
CXCR4 has an unexpected role in inhibiting KC proliferation and mitigating the effects of proliferative T helper
type 17 cytokines.
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INTRODUCTION
Chemokine receptors comprise four homologous families of
seven transmembrane-spanning, G protein–coupled receptors
that activate key intracellular signaling pathways controlling
cell shape, migration (chemotaxis), and proliferation (Nestle
et al., 2009). In inflammatory skin disease, chemokines and
chemokine receptors also have important roles in immune cell
migration into skin (Lonsdorf et al., 2009). Keratinocytes (KCs)
are considered to be a rich source of chemokines such as
CXCL8 (chemokine (C-X-C motif) ligand 8) and CCL20, which
are abundant in psoriatic plaques (Schon and Boehncke,
2005), but the role of chemokine receptors that are
expressed by KCs has not been fully explored. CXCR4, a
chemokine receptor that has multiple roles in cancer
metastasis (Balkwill, 2004), vasculogenesis (Yamaguchi
et al., 2003; Urbich and Dimmeler, 2004), stem cell
recruitment (Petit et al., 2002), and HIV infection (Bleul
et al., 1996), has been detected in proliferating KCs after
burn injury (Avniel et al., 2006). Interestingly, inhibition of
CXCR4 appeared to increase the rate of re-epithelialization
following burn injury (Avniel et al., 2006), suggesting a
regulatory role for CXCR4 in skin repair or re-epithelialization.
In the psoriasis field, clinicians have long been aware of the
Koebner phenomenon (Weiss et al., 2002), and biochemical
evidence has also suggested a link between wound healing
and psoriatic plaques (Mansbridge and Knapp, 1987;
Romanowska et al., 2010). The above-mentioned link
between CXCR4 and wound healing prompted us to explore
the role of CXCR4 in the context of a well-known model of
psoriasiform dermatitis (Chan et al., 2006; Hedrick et al.,
2009; Mabuchi et al., 2011) that is induced by repeated
injections of the proinflammatory cytokine IL-23, a cytokine
that is critical for the maintenance of T helper type 17 cells
(Fitch et al., 2007).
To determine the role of CXCR4 signaling in the epidermis
in the setting of psoriasiform dermatitis, we specifically
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deleted CXCR4 in murine keratin 14 (K14)–positive basal KCs
by crossing mice carrying floxed CXCR4 alleles with those
expressing Cre recombinase under the transcriptional control
of the K14 promoter. We next induced skin inflammation via
repeated injections of IL-23, resulting in psoriasiform derma-
titis (Wilson et al., 2007; Hedrick et al., 2009). Surprisingly,
targeted deletion of CXCR4 in basal KCs resulted in a
markedly exaggerated response to IL-23 in the skin of K14-
CXCR4KO mice. Furthermore, our in vitro studies indicated
that CXCR4 signaling abrogates the proliferative response of
KCs to IL-22 (Zheng et al., 2007) through a mechanism that
requires SOCS3 (suppressor of cytokine signaling 3). In
aggregate, our data strongly suggest that CXCR4 may have
an unsuspected role in regulating epidermal proliferation in
some inflammatory skin conditions.
RESULTS
Targeted deletion of CXCR4 in basal KCs results in exaggerated
psoriasiform changes after IL-23 treatment
We first confirmed that K14-CXCR4KO mice were homozy-
gous for the floxed CXCR4 and Cre genes using PCR
(Supplementary Figure S1 online). Because we were princi-
pally interested in the expression of CXCR4 in epidermal KCs
after IL-23 treatment, we separated the epidermis from the
dermis by standard techniques. Whereas epidermal CXCR4
mRNA was upregulated in CXCR4f/f control mice after IL-23
treatment, K14-CXCR4KO mouse skin showed minimal
expression of epidermal CXCR4 (Figure 1a). On combining
the results of three experiments, the P-value (after combining
three experiments) did not reach significance (P¼ 0.062). It is
known that Langerhans cells, which do not express K14,
express high levels of CXCR4 upon activation, thus accounting
for measurable (and variable) levels of CXCR4 in the epidermis
of K14-CXCR4KO mice. Minimal levels of CXCR4 protein,
possibly from Langerhans cells, were detected in the basal KCs
of K14-CXCR4KO mice versus CXCR4f/f mice by antibody
staining (Supplementary Figure S2 online). CXCR4 was not
detected in phosphate-buffered saline (PBS)–injected CXCR4f/f
(or wild-type (WT)) mice epidermis (data not shown). Thus,
epidermal CXCR4 expression in CXCR4f/f control mice is
upregulated following repeated injection of IL-23, but only
minimally observed in CXCR4KO mouse skin (possibly
because of incomplete deletion of the CXCR4 gene by the
Cre recombinase or unaffected expression of CXCR4 by
Langerhans cells).
Histologically, IL-23-treated ears of K14-CXCR4KO mice
exhibited exaggerated psoriasiform changes compared with
control mice (Figure 1c and d). Specifically, they displayed a
thicker epidermis (Figure 1b), increased parakeratosis with
greater accumulation of neutrophils in the cornified layer, and
a dense inflammatory infiltrate in the dermis (Figure 1c). The
neutrophilic aggregates were subjectively observed more
frequently in the K14-CXCR4KO mice. Although both control
mice and K14-CXCR4KO mice showed epidermal thickening
after IL-23 treatment, K14-CXCR4KO mice ears showed a
2-fold increase compared with CXCR4f/f control mice
(Figure 2a). We also counted infiltrating cells in the dermis
(Figure 1c) and found that the number of infiltrating cells
increased 1.5-fold in K14-CXCR4KO mice compared with
CXCR4f/f control mice (Figure 2b). Ear swelling, a measure-
ment of dermal edema and inflammation, during IL-23
treatment was significantly increased (following analysis of
variance) in K14-CXCR4KO mice on days 4 and 5 compared
with CXCR4f/f control mice, which showed an increase above
day 0 only on day 5 (Figure 2c). Thus, targeted deletion of
CXCR4 in basal KCs results in exaggerated psoriasiform
inflammatory changes after treatment with IL-23.
CXCR4 expression inversely correlates with epidermal
hyperplasia in WT mice following IL-23 treatment
We observed that injection of IL-23 in WT C57BL/6 mice did
not result in completely uniform epidermal hyperplasia
throughout the entire epidermis above the injection site
(Figure 3a). We hypothesized that the expression level of
CXCR4 on basal KCs might regulate epidermal hyperplasia
and thus examined CXCR4 expression by immunofluores-
cence microscopy in basal KCs of WT mice treated with IL-23.
Indeed, CXCR4 expression was enhanced in nonhyperplastic
regions, whereas hyperplastic regions showed little or no
expression of CXCR4 (Figure 3b).
In the IL-23 injection model, IL-22 is produced by immune
cells such as conventional and gd T cells (Mabuchi et al.,
2011), and it induces KC proliferation via signal transducer
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Figure 1. CXCR4 expression in CXCR4f/f control mice (CXCR4f/f-Cre- mice)
and K14-CXCR4KO mice following IL-23 injection. CXCR4KO mice and
CXCR4f/f control mice ears were injected with IL-23 every other day for 5 days
and collected at day 5. Abrogation of CXCR4 expression was shown using real-
time PCR (2–3 ears). (a) Representative results from one of three experiments
with similar results are shown. Hematoxylin and eosin (H&E) staining was
performed for ear sections from K14-CXCR4KO mice and control mice treated
with or without IL-23. Neutrophils in the stratum corneum are indicated by a
black arrow in b and shown at higher magnification in c. Scale bars¼ 100mm.
(b, c) Representative results from one of three experiments with similar results
are shown.
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and activator of transcription 3 (STAT3) activation (Boniface
et al., 2005). As a negative feedback control system for STAT3
signaling, SOCS3 is known to block the STAT3
phosphorylation by JAK (Brantley and Benveniste, 2008).
Thus, we asked whether SOCS3 expression differed between
hyperplastic and nonhyperplastic regions. Similar to the
expression pattern observed with CXCR4, SOCS3 expression
in the basal epidermal layer was markedly reduced in
hyperplastic regions compared with nonhyperplastic regions
(Figure 3c). In summary, CXCR4 and SOCS3 expression on
basal KCs correlates with regions of reduced epidermal
hyperplasia following IL-23 injection, suggesting that CXCR4
may negatively regulate KC proliferation.
IL-22 and CXCL12 synergistically upregulate SOCS3 in CXCR4-
overexpressing HaCaT cells
IL-22 is a key downstream effector molecule that is produced
by both ab and gd T cells (Mabuchi et al., 2012). It mediates
epidermal hyperplasia and inflammation in response to IL-23.
KCs are not believed to respond to IL-23 directly, but they do
possess the IL-22 receptor, which acts through STAT3 to
induce a variety of key changes found in psoriasis (Zheng
et al., 2007). HaCaT cells, a KC-derived cell line, express the
IL-22 receptor (Kreis et al., 2007) and are known to proliferate
in response to IL-22 in vitro (Nakagawa et al., 2011). To
determine whether CXCR4 signaling regulated IL-22-mediated
KC proliferation via SOCS3, we established CXCR4-
overexpressing HaCaT (Boukamp et al., 1988) immortalized
human KC cells (CXCR4-HaCaT) and cultured them in the
presence of IL-22 with or without CXCL12 (chemokine (C-X-C
motif) ligand 12). As expected, IL-22 increased CXCR4-HaCaT
proliferation, whereas CXCL12 alone had little effect on
HaCaT cell proliferation (Figure 4a). Strikingly, co-addition
of CXCL12 blocked the ability of IL-22 to stimulate HaCaT cell
proliferation (Figure 4a), suggesting that CXCR4 activation
functions as an inhibitor when IL-22 signaling is engaged.
The IL-22 receptor was only modestly upregulated in the
presence of IL-22 and CXCL12 compared with IL-22 or
CXCL12 alone (data not shown), indicating that CXCR4 did
not directly regulate the expression of this receptor. We next
asked whether the inhibitors of JAK/STAT3 pathway were
upregulated by coculture of CXCL12 and IL-22. IL-22 induces
the phosphorylation of STAT3, thus promoting the expression
of JAK/STAT3 inhibitors such as SOCS3 and PIAS3 (protein
inhibitor of activated STAT3) as potential negative feed-
back control mechanisms (Brantley and Benveniste, 2008).
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Figure 2. Epidermal thickening and psoriasiform changes in CXCR4f/f control and K14-CXCR4KO mice following IL-23 injection. Ear sections from K14-
CXCR4KO mice (n¼3) and CXCR4f/f control mice (n¼3) were treated with IL-23 every other day for 5 days and were hematoxylin and eosin (H&E) stained.
(a) The subjectively thickest epidermal regions were selected, and epidermal thicknesses were measured at four points in a blinded manner for each mouse
sample. (b) Dermal infiltrating cells were counted on randomly selected sections of IL-23-treated mice (n¼ 3). Ear swelling was measured before injection
(days 0, 2, and 4) and before harvesting ears (day 5; n¼ 3). (a–c) Representative data from one of two independent experiments with similar results are shown.
*Significance using Scheffe´’s post hoc comparison test.
T Takekoshi et al.
CXCR4 and Keratinocyte Proliferation
2532 Journal of Investigative Dermatology (2013), Volume 133
PIAS3 mRNA expression, however, was not affected by
CXCL12, IL-22, or the combination of the two (data not
shown). As expected based on previous reports, SOCS3
mRNA was upregulated in CXCR4-HaCaT cells cultured
with IL-22 for 1 hour (Figure 4b). CXCL12 had little impact
on SOCS3 expression by itself, but the addition of CXCL12 in
the presence of IL-22 synergistically enhanced SOCS3 mRNA
level (Figure 4b). To confirm this result at the protein level, we
observed enhanced SOCS3 upregulation in CXCR4-HaCaT
cells cultured with IL-22 and CXCL12 using quantitative
immunofluorescence microscopy (Supplementary Figure S3
online).
We next asked whether the observed SOCS3 upregulation
inhibited the JAK/STAT3 pathway with the knowledge that
SOCS3 attenuates STAT3 phosphorylation at Tyr705 (Linke
et al., 2010), a key activation site, following exposure to IL-22
(Sestito et al., 2011). As shown in Figure 4c (full-length blot is
shown in Supplementary Figure S4 online), IL-22, but not
CXCL12, induced marked phosphorylation of STAT3. The
addition of CXCL12 with IL-22, however, reduced the levels
of phosphorylated STAT3 by 33.4±2.5% (mean±SD from
three independent experiments) without affecting total STAT3.
Thus, CXCR4-HaCAt cells cultured with IL-22 and CXCL12
show reduction in activated pSTAT3 at a key phosphorylation
site.
We next asked whether SOCS3 was required for CXCR4-
mediated inhibition of CXCR4-HaCaT cell proliferation.
CXCR4-HaCaT cells were transiently transfected with small
interfering RNA (siRNA) that specifically targeted SOCS3 and
were then cultured with IL-22 and CXCL12. We confirmed
that SOCS3 siRNA inhibited SOCS3 expression in CXCR4-
HaCaT cells cultured with IL-22 and CXCL12 (Supplementary
Figure S5 online). It is noteworthy that CXCR4-HaCaT cell
proliferation was restored when cells were treated with
SOCS3-specific siRNA in the presence of IL-22 and CXCL12,
but not with nonspecific control siRNA (Figure 4d). Thus,
CXCL12 in combination with IL-22 synergistically enhances
SOCS3 expression in CXCR4-HaCaT cells, reduces phosphor-
ylation of STAT3 at a critical tyrosine site, and blocks HaCaT
cell proliferation via a SOCS3-dependent mechanism.
CXCR4 and SOCS3 are upregulated in the junctional zone
between lesional and perilesional regions in human psoriatic skin
Finally, we asked whether CXCR4 was upregulated in human
psoriatic skin lesions. The biopsied samples that we examined
were taken from the border of psoriatic plaques and contained
lesional hyperplastic areas as well as the transitional area
(junctional zone) between clinically psoriatic and nonpsoriatic
skin (Figure 5a). The junctional zone showed moderate
epidermal hyperplasia compared with perilesional regions
(Figure 5a). Strong CXCR4 expression was observed in basal
KCs in the junctional zone (Figure 5b; upper-left panel)
between lesional and perilesional regions. CXCR4, however,
was only focally present in lesional regions (Figure 5b; middle
panel) and was nearly completely absent in perilesional
regions (data not shown). We calculated the ratio of CXCR4-
positive area to either the junctional or lesional zone areas of
psoriatic epidermis and found a significant difference
(Figure 5b; right panel). Control human skin from nonpsoriatic,
healthy patients showed little or no CXCR4 staining (Figure 5b;
lower-middle panel). We next stained psoriatic skin sections
with anti-SOCS3 antibody and noted increased SOCS3
expression in the junctional zone (Figure 5c; left panel). In
samples taken from the same patient, lesional psoriasis regions
that showed weak CXCR4 staining at the basal layer of the
epidermis (Figure 5b; middle panel) also showed weak SOCS3
staining (Figure 5c; middle panel). The ratio of SOCS3-positive
area to the entire junctional or lesional zones was also
significantly higher in junctional zones (Figure 5c; right panel).
Weak SOCS3 expression in normal human skin was shown to
be almost the same as that in psoriasis lesional skin (Horiuchi
et al., 2006). Similar results were noted in two additional
psoriatic patients (data not shown). Thus, CXCR4 and SOCS3
were both upregulated at the junctional zone of psoriatic
lesions, suggesting that the expression of these two proteins
may be a biomarker for the transition between hyperplastic
psoriatic plaques and clinically nonaffected skin.
DISCUSSION
CXCR4 has been shown in several cancer systems to positively
regulate proliferation, survival, and metastasis (Murakami
et al., 2002, 2003; Dell’Agnola and Biragyn, 2007). Thus,
we were surprised to see strikingly enhanced epidermal
hyperplasia and parakeratosis in K14-CXCR4KO mice
following IL-23 treatment. Previous reports showed that
CXCR4 signaling can upregulate SOCS expression and
inactive growth hormone function (Garzon et al., 2004).
In our in vitro model, combined treatment with CXCL12 and
IL-22 synergistically induced SOCS3 expression and reduced
phosphorylation of STAT3. In contrast to the work of Garzon
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Figure 3. Epidermal expression of CXCR4 and SOCS3 (suppressor of cytokine
signaling 3) in wild type (WT) mice following IL-23 treatment. Ear sections
from WT mice (n¼3) treated with IL-23 were hematoxylin and eosin (H&E)
stained and digitally photographed. (a) Representative H&E-stained sections
from thick and thin epidermal regions of WT mice treated with IL-23 are
shown. Skin from WT mice treated with IL-23 were stained with (b) anti-
CXCR4 and (c) anti-SOCS3 antibodies, and representative thick and thin
epidermal regions were selected for illustration of differential antibody staining.
Scale bars¼ 100mm. The superior dotted lines in b and c represent the
approximate level of the cornified layer, whereas the inferior (or single) dotted
lines in b and c represent the approximate level of the epidermal basement
membrane. DAPI, 4’,6-diamidino-2-phenylindole.
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et al. (2004), CXCL12 alone induced little, or no, SOCS3
expression, which may be a reflection of the different cell type
used in our system.
In human psoriasis skin samples, we observed strong
CXCR4 expression in the junctional zone between lesional
and perilesional regions. Increased SOCS3 expression was
also detected in this area, further strengthening a possible
relationship between CXCR4 and SOCS3 in controlling
epidermal proliferation. We hypothesize that the coordinated
upregulation of CXCR4 and SOCS3 at the border between
affected and unaffected skin may provide a molecular expla-
nation for the abrupt transition from affected to unaffected skin
that is so highly characteristic of psoriasis lesions.
In this work, we do not directly address which signaling
mechanisms govern CXCR4 upregulation in the junctional
zones of lesional skin. CXCR4, however, is known to be
positively regulated by hypoxia-inducible factor (Staller et al.,
2003), which is strongly upregulated in psoriatic skin
(Rosenberger et al., 2007). Our results suggest that CXCR4
(and SOCS3) upregulation may be a counter mechanism to
balance the highly proliferative cytokine signals that are
present in psoriatic lesions and to limit the circumferential
expansion of psoriatic plaques. Given the limited amount of
human tissue available to us that contained lesional, junction,
and nonlesional areas, our results will need to be confirmed
with larger numbers of psoriatic tissue samples. In aggregate,
our data suggest that drugs that upregulate CXCR4 function or
expression might be helpful in the setting of psoriasis or other
hyperproliferative diseases.
As illustrated in Figure 6a, upregulation of SOCS3 is a well-
known negative feedback mechanism that balances the effect
of STAT3 activation. In psoriatic lesions, however, SOCS3 is
apparently not expressed at sufficient levels to block KC
proliferation in the presence of STAT3-dependent inflamma-
tory cytokines such as IL-22. CXCR4-mediated signaling,
however, synergistically upregulates SOCS3, leading to
reduced phosphorylation of STAT3, and, subsequently, to
the reduced ability of HaCaT cells to proliferate in vitro in
response to IL-22 (Figure 6b). Our in vitro data are comple-
mented by our in vivo data showing profound loss of CXCR4
and SOCS3 expression in thick epidermal regions compared
with the thin epidermal regions of IL-23-treated WT mice.
CXCR4 may be essential for downregulating KC proliferation
and thus mitigating the effects of proliferative cytokines such
as IL-23 and IL-22 under inflammatory conditions. It remains
to be determined whether or not CXCR4 affects the degree of
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Figure 4. Effects of CXCL12 (chemokine (C-X-C motif) ligand 12) on HaCaT cell proliferation, SOCS3 expression, and phosphorylation of STAT3 (signal transducer
and activator of transcription 3). CXCR4-HaCaT cells were cultured for 1 day, and then with human CXCL12 and/or human IL-22. After 2 more days (n¼5 wells/
condition), cells were counted. (a) Summary of three independent experiments is shown. CXCR4-HaCaT cells were stimulated with CXCL12 and/or IL-22 for
1 hour. (b) SOCS3 mRNA expression was measured using real-time reverse transcriptase–PCR (RT–PCR; n¼ 3 wells/condition; one of three experiments shown).
(c) Phospho-STAT3 (pSTAT3) and total STAT3 were examined by western blotting (representative experiment shown). (c) Analysis by densitometry (normalized
using vehicle-treated cells) of three independent experiments is shown in the lower panel. (d) CXCR4-HaCaT cells were transfected with SOCS3 small interfering
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inflammation in other inflammatory skin diseases that do not
show enhanced epidermal hyperplasia.
MATERIALS AND METHODS
Mice
C57BL/6 WT mice, 8 and 12 weeks old, were purchased from Charles
River Laboratories. Tissue-specific knockout mice were generated
using a Cre-loxP (Wilminton, MA) approach (Nagy, 2000;
Zimmerman et al., 2011). Heterozygous C57BL/6J mice carrying a
floxed CXCR4 allele (CXCR4f/wt) were originally obtained from
Dr Daniel Littman (Howard Hughes Medical Institute, New York
University, New York, NY). To selectively inactivate CXCR4 in basal
KCs, CXCR4f/f mice were crossed with transgenic mice expressing the
Cre recombinase under the transcriptional control of the K14
promoter (STOCK Tg (KRT14-cre) 1Amc/J; Jackson Laboratories, Bar
Harbor, ME). Animal protocols were approved by the institutional
animal care and use committee at the Medical College of Wisconsin.
Human psoriasis skin samples
Clinical protocols in accordance with the Declaration of Helsinki
Principles that approved collection of human psoriasis skin sample
were obtained from the institutional ethical committee of the Faculty
of Medicine, University of Tokyo. All subjects signed written
informed consent. Skin biopsies from the border of psoriatic lesions
were taken from three patients (Supplementary Table S1 online) with
typical psoriasis lesion by excisional biopsy. Skin samples were
embedded in optimal cutting temperature compound, frozen, and
then sectioned.
Genotyping of tissue-specific knockout mice
Mouse DNA was extracted from tail tissue using DNeasy Blood &
Tissue Kit (Qiagen). PCR using Taq DNA polymerase (Qiagen,
Germantown, MD) was performed. The forward and reverse
primers used for PCR are shown in Supplementary Table S2
online.
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Figure 5. CXCR4 and SOCS3 expression in human psoriatic skin. Three human psoriasis skin samples containing the junctional zone between lesional and
perilesional regions were biopsied (see Supplementary Table S1 online). (a) An example of hematoxylin and eosin (H&E) stainings showing these regions is shown
(patient 1). (b) CXCR4 and (c) SOCS3 stainings of the junctional and lesional area were performed, and representative images of similar findings are depicted
(patient 2; see Supplementary Figure S6online). A healthy human skin sample was stained using anti-CXCR4 Ab (b; lower-left panel). CXCR4- and SOCS3-positive
areas of three psoriasis patients were quantified using ImageJ software and used for the calculation of the ratio (%) of marker-positive area to epidermal junctional
or lesional zone areas (right panels of b and c). Scale bars¼ 100mm.
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Retroviral transduction of HaCaT human KC cell line
HaCaT cells were transduced with hCXCR4 complementary DNA
using the pLNCX2 retroviral vector (Clontech, Mountain View, CA) as
previously described (Fang et al., 2008). CXCR4-overexpressing
HaCaT cells (CXCR4-HaCaT) were grown in MEM (Invitrogen,
Grand Island, NY) with 10% heat-inactivated fetal bovine serum
(Biowest, Kansos City, MO).
Cell proliferation assay
CXCR4-HaCaT cells (2 104) were cultured in a six-well plate for
1 day, followed by incubation with recombinant human CXCL12
(Dr Brian Volkman, Biochemistry, Medical College of Wisconsin;
Veldkamp et al., 2009) and/or recombinant human IL-22 for 2 days.
Cells were trypsinized, washed with PBS, and resuspended in
CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison,
WI) for measurement of luciferase activity.
siRNA transfection
siRNAs for SOCS3 (Silencer Select Pre-designed siRNA, s17189) and
nonspecific control (Silencer Select Negative Control #1 siRNA) were
purchased from Ambion (Grand Island, NY). They were used for
transfection of CXCR4-HaCaT cells using Lipofectamine 2000 (Invi-
trogen) according to the manufacturer’s protocol.
IL-23 injection model
Recombinant mouse IL-23 (500 ng per site in 20ml PBS; eBioscience,
San Diego, CA) was injected into the ears of anesthetized mice every
other day for 6 days, as described previously (Hedrick et al., 2009).
After harvesting mice ears, ventral skin sheets were incubated in PBS
containing 0.5% trypsin (US Biochemical, Clevelond, OH) for
40 minutes at 37 1C to separate the epidermis from the dermis. To
obtain cell suspensions, epidermal sheets were repeatedly minced
with scissors (Salgado et al., 1999). Cells were then filtered and
washed with PBS before use.
Quantitative real-time reverse transcriptase–PCR
The extraction of RNA and complementary DNA synthesis from
epidermal or dermal cell suspensions were performed using an
RNeasy Kit (Qiagen) and High Capacity complementary DNA
Reverse Transcription Kits (Applied Biosystems, Carlsbad, CA).
Reverse transcriptase–PCR was performed via StepOnePlus Real-Time
PCR System (Applied Biosystems) using the SYBR Green PCR master
mix (Applied Biosystems). We confirmed PCR quality by performing
melting curve analysis each time. The forward and reverse primers
used for real-time reverse transcriptase–PCR are shown in Supple-
mentary Table S2 online (Integrated DNA Technologies, Coralville, IA).
Western blotting
Total proteins were extracted using RIPA buffer (Sigma-Aldrich,
St Louis, MO) containing protease inhibitor cocktail (Roche, Branford,
CT). After centrifugation, supernatants were collected and cell lysates
were reduced, boiled, loaded onto 4–12% Bis-Tris gel (Invitrogen),
and transferred to nitrocellulose membranes (Invitrogen). Membranes
were blocked with 2% BSA (Sigma-Aldrich) for 1 hour and incubated
with anti-phosphorylated STAT3 mAb (Santa Cruz, Dallas, TX) at
1:200 dilutions for 1 hour or with anti-STAT3 p92 polyclonal antibody
(eBioscience) at 1:500 overnight. Membranes were then washed three
times and incubated with horseradish peroxidase–conjugated goat
anti-mouse IgG (Santa Cruz) or with horseradish peroxidase–
conjugated donkey anti-rabbit IgG (Santa Cruz) at 1:500 dilutions
for 1 hour. After washing, membranes were incubated with chemilu-
minescent solution (ECL Western Blotting Detection Reagents; GE
Healthcare (Pittsburgh, PA)) for 5 minutes at room temperature.
Images were acquired using the ChemiDoc XRSþ system (Bio-Rad,
Hercules, CA). Densitometry analysis was performed using the ImageJ
1.45s software (NIH, Bethesda, MD). When required, membranes
were incubated in stripping buffer (Thermo Fisher Scientific,
Waltham, MA) for 30 minutes at 37 1C to remove bound antibodies.
Immunohistochemistry
Anti-CXCR4 (C-20) and anti-SOCS3 antibody (M-20; Santa Cruz) in
combination with Alexa Fluor 568 donkey anti-goat IgG (Hþ L)
secondary antibodies were used alone or with corresponding target
peptides as specificity controls.
Mouse ears were excised, embedded in optimal cutting tempera-
ture compound without fixation, frozen, and then sectioned. CXCR4-
HaCaT cells were cultured in Lab-TekII Chamber Slides (Thermo
Scientific) for 1 day, followed by serum deprivation for 1 day. Cells
were then incubated with cytokines for 1 hour and were air-dried. For
CXCR4 staining, tissue sections were fixed with ice-cold acetone for
10 minutes (CXCR4 staining) or with 4% paraformaldehyde PBS
solution for 10 minutes, followed by incubation with 95% ethanol
for 20 minutes (SOCS3 staining); they were then blocked for 1 hour at
room temperature with 5% donkey serum, Fc-blocker (2.4G2; Bio X
Cell, W. Lebanon, NH), and donkey anti-goat IgG horseradish
peroxidase (Santa Cruz) in PBS containing 3% skim milk. Sections
were incubated with primary antibody overnight at 4 1C, followed by
incubation with secondary antibody for 30 minutes at room tempera-
ture and with SlowFade Gold Antifade Reagent with 4’,6-diamidino-
2-phenylindole (DAPI; Invitrogen). After image acquisition, the
ImageJ 1.45s software (NIH) was used for quantification. For
measuring epidermal hyperplasia, we selected the thickest epidermal
regions from each mouse ear sample and measured the epidermal
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Figure 6. Schematic model of the role of CXCR4 and CXCL12 (chemokine
(C-X-C motif) ligand 12) in IL-22-mediated keratinocyte (KC) proliferation.
A schematic model for IL-22, CXCL12, and SOCS3 (suppressor of cytokine
signaling 3) regulation of KC proliferation is shown. (a) JAK/signal transducer
and activator of transcription 3 (STAT3) pathway is activated by IL-22 and
results in modest upregulation of SOCS3, which is insufficient to downregulate
keratinocyte proliferation. (b) However, SOCS3 expression is synergistically
upregulated in the presence of IL-22, CXCR4, and CXCL12, resulting in the
abrogation of STAT3 signaling and marked inhibition of KC proliferation.
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thickness at four random points in a blinded manner. We counted
infiltrating cells to the dermis in a blinded manner.
Statistical analysis
All quantitative data were shown as the mean±SD unless otherwise
indicated. Simple comparisons of means and SD of data were made
by using Student’s t-test, and post hoc multiple comparisons (indi-
cated by * next to P-values) were made with one-way analysis of
variance and Scheffe´’s test, using the Statcel statistical analysis
software package (OMS Publishing, Saitama, Japan).
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